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ABSTRACT
Patients with anterior cruciate ligament (ACL) rupture are two times as likely to develop posttraumatic osteoarthritis (PTOA).
Annually, there are900,000 knee injuries in the United States, which account for12% of all osteoarthritis (OA) cases. PTOA leads
to reduced physical activity, deconditioning of themusculoskeletal system, and in severe cases requires joint replacement to restore
function. Therefore, treatments that would prevent cartilage degradation post-injury would provide attractive alternatives to
surgery. Sclerostin (Sost), a Wnt antagonist and a potent negative regulator of bone formation, has recently been implicated in
regulating chondrocyte function in OA. To determine whether elevated levels of Sost play a protective role in PTOA, we examined
the progression of OA using a noninvasive tibial compression overload model in SOST transgenic (SOSTTG) and knockout (Sost-/-)
mice. Here we report that SOSTTG mice develop moderate OA and display significantly less advanced PTOA phenotype at 16 weeks
post-injury compared with wild-type (WT) controls and Sost-/-. In addition, SOSTTG built 50% and 65% less osteophyte volume
than WT and Sost-/-, respectively. Quantification of metalloproteinase (MMP) activity showed that SOSTTG had 2-fold less MMP
activation than WT or Sost-/-, and this was supported by a significant reduction in MMP2/3 protein levels, suggesting that elevated
levels of SOST inhibit the activity of proteolytic enzymes known to degrade articular cartilage matrix. Furthermore, intra-articular
administration of recombinant Sost protein, immediately post-injury, also significantly decreasedMMP activity levels relative to PBS-
treated controls, and Sost activation in response to injury was TNFa and NF-kB dependent. These results provide in vivo evidence
that sclerostin functions as a protective molecule immediately after joint injury to prevent cartilage degradation. © 2018 The
Authors. Journal of Bone and Mineral Research Published by Wiley Periodicals Inc.
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Introduction
The increased risk of developing knee osteoarthritis (OA) afterinjury to the anterior cruciate ligament (ACL) has been well
documented both clinically and in experimental models.(1,2)
Clinical manifestation of posttraumatic osteoarthritis (PTOA) is
characterized by narrowing of the joint space, emergence of
osteophytes through osteoarthritic remodeling, cartilage ero-
sion, and fibrillation.(2) Biomechanical disturbances in the joint
such as lateral subluxation of the tibia further the development
of osteophytes in the lateral tibial-femoral compartment and
cause misalignment, rotation, and anterior subluxation of the
joint; all these physical manifestations contribute to the
emergence of intra-articular lesions. Cartilage lesions become
further exacerbated through molecular changes in the joint,
including the increase in the production of matrix-degrading
enzymes, such as aggrecanases andmetalloproteinases (MMPs).
Elevated levels of catabolic enzymes enhance the loss of
articular cartilage,(3) increase the amount of pain experienced,
and lead to impaired joint mobility in >50% of individuals who
sustained an ACL tear.(4,5) In addition to changes in joint
architecture and uneven biomechanical load distribution in the
knee after ACL tear, the individual susceptibilities to inflamma-
tory responses, enzymatic cartilage destruction, and osteophyte
formation will also determine subsequent osteoarthritic
outcomes.
Wnt/b-catenin signaling was previously implicated in OA
pathogenesis.(6) Conditional activation of b-catenin in the
articular chondrocytes of adultmice resulted in reduced articular
cartilage area, surface fibrillation, vertical clefting, and
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osteophyte formation, independent of trauma, suggesting that
activation of Wnt signaling in the articular cartilage causes OA-
like phenotypes.(7) Furthermore, b-catenin has been shown to
stimulate the activity of catabolic enzymes in the extracellular
matrix (ECM) of the cartilage.(8) These findings suggest that bone
and cartilage are regulated by similar but functionally opposing
mechanisms, where Wnt signaling is anabolic in bone but
catabolic in the cartilage.(9) Sclerostin (Sost) is a potent negative
regulator of bone mass, where it normally inhibits Wnt signaling
through interactions with low-density lipoprotein receptor-
related protein (LRP) 5/6 co-receptors.(10,11) In the absence of
Sost protein, patients develop two types of hyperostosis,
sclerosteosis and van Buchem disease.(12,13) Consistent with
the human hyperosteosis, Sost-deficient mice (Sost-/-) also
acquire a generalized high bone mass phenotype.(14,15)
Conversely, transgenic mice overexpressing SOST (SOSTTG or
TG) are osteopenic.(16)
Until recently, Sost expression has been described as
osteocyte-specific, but several reports have now shown that
Sost is also expressed in the articular cartilage. Elevated levels of
Sost were observed in chondrocytes near damaged sites in the
articular cartilage of mice and sheep subjected to surgical
models of OA.(6,17) Similarly, transcriptional analysis found SOST
to be upregulated14-fold in cartilage derived from biopsies of
OA patients undergoing joint replacement surgery,(18) suggest-
ing that upregulation of SOST in cartilage may have a protective
role. Although these observations have been correlative, in vivo
evidence has been lacking in support of Sost as an anti-catabolic
agent in the joint. Here we investigated the role of Sost in the
articular cartilage and found SOST to inhibit cartilage degrada-
tion subsequence to traumatic injury by downregulating
catabolic enzymes whose expression is Wnt-dependent. These
findings suggest that elevated levels of Sost, immediately after
injury, can aid the joint in maintaining its articular cartilage
integrity in PTOA.
Materials and Methods
Mice strains and tibial compression OA injury
Sost-/- and SOSTTG mice have been previously described and are
on C57Bl/6 background.(15,16) Sost-/- allele was generated by
replacing the open reading frame with the LacZ reporter.(19)
SOSTTG express a 158-kb human bacterial artificial chromo-
some (BAC; RM11-209M4) that encompasses three genes
(DUSP3, SOST, MEOX1) and the 90-kb noncoding interval
separating SOST from MEOX1; therefore, human SOST expres-
sion is physiological and regulated by endogenous human
regulatory elements.(16) Both Sost-/- and SOSTTG were back-
crossed to C57Bl/6 >10 generations. Sost-/- and SOSTTG were
genotyped by PCR. Some SOSTTG animals display limb defects;
only normal and animals missing one digit (thumb only) were
used in these experiments. Mice were injured at 16 weeks of age
using a previously described tibial compression OA injury
model.(1) In brief, a single dynamic compressive loadwas applied
to the stationary (right) knee joint displacing the tibial condyle
over the femoral condyle to induce an anterior cruciate ligament
(ACL) rupture. In vivo experiments utilized a minimum of 5
animals (n 5) to reach statistical significance. All mice (C57Bl/6,
Sost-/- and SOSTTG) examined were bred in-house and housed 2
to 3 animals per cage. Mice were allowed unlimited free range of
food (Envigo, EastMillstone, NJ, USA; cat. 2918, 18%protein) and
water; mice were on a 12-hour lights on/off cycle. All animal
procedures were carried out in accordance with guidelines
under the Institutional Animal Care and Use Committees at
Lawrence Livermore National Laboratory and University of
California, Davis.
Histology and OA evaluation
Injured and uninjured joints were dissected free of soft tissue,
fixed, dehydrated, paraffin embedded, and sectioned as
previously described.(20) To visualize the cartilage, sagittal
6-mm paraffin serial sections were stained with Safranin-O
(0.1%, Sigma, St. Louis, MO, USA; S8884) and Fast Green (0.05%,
Sigma; F7252) using standard protocol from IHC world website.
OA severity was evaluated at 1 day and 6-, 12-, and 16-weeks
after injury on sagittal sections using a modified osteoarthritis
research society international (OARSI) scoring scale, as previ-
ously described.(21) Starting from the synovium membrane to
the articular cartilage, for each region, cartilage scoring began
0.4mm out from the start of synovium. Blinded slides were
evaluated by three scientists (two with and one without
expertise in OA) utilizing a modified (sagittal) OARSI scoring
parameter.(21)
Immunohistochemistry (IHC)
Sagittal serial sections were stained utilizing primary antibodies
directed to mouse Sost (R&D Systems, Minneapolis, MN, USA;
AF1589 [1mg/mL]), human SOST (Abcam, Cambridge, MA, USA;
ab75914 [100mg/mL]), Collagen II (Abcam; ab21291 [1:50]),
activated b-catenin (Millipore, Billerica, MA, USA; 05-665 [10mg/
mL]), MMP 2 (Abcam; ab110186 [5mg/mL]), MMP 3 (Abcam;
ab52915 [7.04mg/mL]), MMP9 (Abcam; ab137867 [10.22mg/
mL]), MMP14 (Abcam; ab53712 [10mg/mL]), and Furin (Abcam;
ab3467 [20mg/mL]). Trypsin/EDTAwas used for antigen retrieval
in 37°C for 30 minutes for all primary antibody except for
activated b-catenin and MMPs 2, 3, 9, and Furin, which required
Uni-trieve (Innovex Biosciences, Richmond, CA, USA) in 65°C for
30 minutes. After Uni-trieve, activated b-catenin and Furin
require an additional retrieval with Proteinase K (Ambion,
Austin, TX, USA; AM2546 [20mg/mL]) for 20 minutes. This was
followed by using Alexa-Fluor 488 (green) or 594 (red)
(Molecular Probes, Eugene, OR, USA) to determine protein
expression.
Micro-computed tomography (mCT)
The subchondral trabecular bone of the femoral epiphysis and
the osteophyte volume quantifications were carried out as
previously described.(22)
RNA sequencing (RNA-seq)
Methodology was previously described.(20) Briefly, whole knee
joints were dissected, chopped, homogenized in Qiazol (79306,
Qiagen, Valencia, CA, USA) lysis solution, and a fraction (1mL) of
the homogenate was used per RNA isolation. Isolated RNA
(1–2mg) was sequenced using Illumina (San Diego, CA, USA)
HiSeq instrument, and a quality check was performed using
FastQC (http://www.bioinformatics.babraham.ac.uk/projects/
fastqc/). The reads were subsequently mapped to mouse
genome (mm10) using TopHat.(23,24) Transcriptome assembly
was performed using Cufflinks, and data was normalized using
Cuffnorm.(24,25) A t test was performed to identify significantly
(p< 0.05) differentially expressed (1.5-fold) genes.
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Quantitative real-time PCR (qPCR)
Total RNA was purified using RNeasy Mini Kit (Qiagen),
subsequent reverse transcription was done by Superscript III
First-Strand Synthesis System (Invitrogen, Carlsbad, CA, USA)
with oligodT primers, and real-time qPCR was performed with
SYBR Select Master Mix (Applied Biosystems, Carlsbad, CA, USA);
all were used according to the manufacturer’s protocol. Applied
Biosystems 7900HT Fast Real-Time PCR Systemwas utilized with
the following cycling conditions: 50°C for 2 minutes for SYBR,
then 95°C for 3 minutes (2 minutes for SYBR), followed by 40
cycles of 95°C for 3 seconds (10 seconds for SYBR) and 30
seconds at 60°C. Data were normalized to control genes
(GAPDH), and fold changes were calculated using the compara-
tive Ct method.(26) Three independent replicates (each whole
joint RNA) were analyzed for each genotype. The following
primers were used: mouse Sost, 50-AGCCTTCAGGAATGATGC-
CAC-30 and 50-CTTTGGCGTCATAGGGATGGT-30; GAPDH, 50-
CCAATGTGTCCGTCGTGGATCT-30 and 50-CCTCAGTGTAGCCCAA-
GATGC-30.
ChIP-seq data analysis and transfections
NF-kB binding sites were identified by mapping ENCODE NF-kB
(RELA) ChIP-seq data sets to SOST locus (hg19) using UCSC
genome browser. NF-kB binding sites in hg19 coordinates were
mapped to mm10 using ECR browser(27) and conserved binding
sites were identified. NF-kB elements were PCRed from mouse
genomic DNA using the primers listed in Table 1 and were
cloned upstream of the TK promoter into the EcoRI site of
GlucTK-mini vector. ATDC5 cells were plated at 10% confluency
in a 24-well plate and cultured in differentiating media (DMEM/
F12þ 5% FBSþ insulin) for 7 days before transfection with
media changes every 2 to 3 days. Plasmids were transfected
using fugene 6 with a fugene/DNA ratio of 1:3. Twenty-four
hours after transfection, cells were treated with 100 ng/mL
TNFa. Luciferase activity was measured 24 hours after TNFa
treatment.
MMP activity (MMPSense) and intra-articular (IA)
injections
MMPSense (PerkinElmer, Waltham, MA, USA; NEV10168) was
administered intravenously 5 hours after injury. Animals (PBS
control [n¼ 5], IA experimental [n¼ 8]) were euthanized, skin
was removed, and the joints were scanned using a Kodak
(Rochester, NY, USA) image station 4000R digital imaging system
at excitation and emission wavelengths of 750 20 nm and
790 20 nm, respectively. The fluorescent intensity of the
uninjured knee joint was used as background and the
fluorescent intensity of the injured knee reported here was
background subtracted from the uninjured knee joint. Ten-
week-old WT male mice were injured, received three doses of
recombinantmouse Sost (rmSost, R&D Systems 1589-ST-025/CF;
4mg/kg) intra-articularly (10mL volume) starting 4 hours after
injury, and in vivo imaging was taken in the same manner as
MMPSense. Refer Fig. 4A for time line. IA administration of NF-kB
inhibitor (Bay-11-7082 [Sigma; 196870]; 4mg/kg) and TNFa
inhibitor (neutralizingmonoclonal antibody [Abcam; ab185795];
4mg/kg) were introduced in the same manner as rmSost.
Dimethyl sulfoxide (DMSO) and saline were used as controls for
NF-kB and TNFa inhibitor, respectively. Refer Fig. 3A for time
line.
Statistical analysis
Two-way ANOVA was performed using GraphPad (La Jolla, CA,
USA) Prism 6 software when evaluating OA severity (aged-
matched uninjured and contralateral between genotypes). In
addition, two-way ANOVA of pairwise comparisons between
injured and contralateral joints and among genotypes were also
performed. A p value of less than 0.05 was considered
statistically significant. The standard error of mean (SEM) were
presented in the error bars.
Results
SOSTTG mice develop a less severe PTOA phenotype
post-ACL injury
Using a tibial compression PTOA mouse model,(1) we examined
whether chronic exposure to elevated levels of SOST would
impact OA outcomes post-injury. SOSTTG, Sost-/-, and C57Bl6
control (WT) mice were examined histologically and by micro-
computed tomography (mCT) at 1 day and 6-, 12-, and 16-weeks
after injury. C57Bl6 have been previously shown to have a mild
PTOA phenotype at 8 weeks after injury,(1) therefore carrying out
the study to 16 weeks post-injury would allow us to capture any
beneficial effects overexpression of SOST would have upon
PTOA development. Although the lateral compartments of the
knees were relatively normal in all genotypes (Supplemental
Fig. S1A), significant differences were observed in the medial
compartments at every time point examined (Fig. 1). Injured and
uninjured joints were indistinguishable, across all genotypes, at
1 day after injury (Supplemental Fig. S1B), indicating that the
cartilage and bone were not damaged by the compressive
overload.(1) The biomechanical destabilization and lateral
subluxation of the joint promoted significant erosion of both
cartilage and bone on the femoral and tibial posterior side
(Fig. 1A, regions I and III) of the medial compartment of the joint
in all genotypes.
However, at 16 weeks after injury, SOSTTG retained signifi-
cantly more of the articular cartilage integrity throughout the
joint, whereasWT and Sost-/- joints displayed significant erosion
below the growth plate of the posterior tibial plateaus (Fig. 1A,
region III). Interestingly, minor fibrillations and clefts down
Table 1. NF-kB Putative Binding Sites Within Sost Locus
NF-kB binding sites (mm10) Distance from TSS Primers for PCR Size (bp) ECR name
chr11:101968161-101969174 –1146a ccagaatccacctgcctttcc/cctatctctctggaccctcct 1111 NF-k1
chr11:101919485-101920334 þ47530 gggtatcgaatgcaggtcagc/gcttgcccaagtcacacaca 927 NF-k2
chr11:101904120-101905739 þ62895 ggagggagccctttagttcag/caaggcatgggtctgaggac 1672 NF-k3
TSS¼ transcription start site; ECR¼ evolutionary conserved region.
aChipSeq hits map to promoter region, defined as 2 kb upstream of TSS. All binding sites map to ECRs (>100 bp; >70% human/mouse identity).
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below the superficial zone of the articular cartilagewere obvious
in the femoral cartilage in all three genotypes (Fig. 1A, region I),
whereas the anterior tibial cartilage remains relatively unaf-
fected (Fig. 1A, region II). Examination of the sagittal views of the
joints by amodifiedOARSI grading scale determined that SOSTTG
had a significantly less severe cartilage loss phenotype than
either Sost-/- or WT joints (Fig. 1B). Furthermore, although
anterior-tibial surface remained largely unchanged after injury,
the femoral and tibial posterior compartment were significantly
different between injured and contralateral joints. SOSTTG
retained most cartilage integrity at 16 weeks after injury
(Fig. 1Av, w, x). The erosion on the posterior side of the tibia
proceeded beyond the growth plate in both WT and Sost-/-
injured joints, whereas the growth plate was relatively intact in
SOSTTG (Fig. 1Ax) These results imply that chronic exposure to
high SOST levels preserves cartilage thickness, suggesting that
elevated levels of sclerostin in the joint improves subsequent OA
outcomes in response to ACL rupture.
Sost/SOST is upregulated in the articular cartilage post-
injury by an NF-kB dependent mechanism
Because Sost is not robustly expressed in the articular cartilage
and Sost-/- mice do not exhibit a dramatic PTOA-like phenotype
in uninjured controls,(16,28) we examined whether Sost expres-
sion is inducible post-injury in the absence of cartilage erosion,
Fig. 1. Moderate PTOA phenotype in SOSTTG comparedwithWT and Sost-/-. Histological staining of Safranin-O and Fast Green on contralateral (left knee)
at 16 weeks post-injury (A). Cartilage integrity scoring using three distinct regions: femoral surface (I); anterior tibial surface (II); and the posterior tibial
surface (III). Lower magnification (5) of whole joint overview between C57Bl/6 (a, e), Sost-/- (i, m), and SOSTTG (q, u); higher-resolution (20) images are
provided for all other images. Injured and contralateral joints were examined and scored in three distinct regions using amodifiedOARSI scoringmethod
(OA severity: 02, mild; 34, moderate; and 56, severe). Uninjured control (UIC) and contralateral (left knee) were utilized as controls. Scale
bar¼ 0.2mm. p< 0.05, p< 0.001. Erosion to the growth plate is marked by asterisks (e, m). Black arrows indicated regions of erosion.
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as previously described.(17) Low levels of Sost-positive chon-
drocytes were observed in the deep zone of articular cartilage
for both WT (Fig. 2A) and SOSTTG (Fig. 2E) uninjured
(contralateral) joints. Consistent with previous reports by
Chan and colleagues(17) in a surgical model of OA, we found
endogenous levels of Sost (Fig. 2B, C, F, G) as well as transgenic
levels of SOST (Fig. 2J, K) to dramatically elevate in femoral and
tibial cartilage, at 1 day after injury, primarily in the deep zone of
Fig. 2. Sclerostin upregulates in the articular cartilage post-injury. Sost immunostaining was conducted on contralateral WT (A) and SOSTTG (E and I) joints at
1day after injury. InjuredWT joints hadelevated levels of Sost (B andC), while injured SOSTTG joints hadelevated expressionof bothmouse (F andG) andhuman
Sclerostin (J and K) 1 day after injury. No differences were observed in Sclerostin expression in the osteocytes of injured animals (D, H, and L). Real-time
quantitative PCR (qPCR) analysis of whole-joint RNA of WTs at 1, 2, 3, and 4 days after injury (M). All images are at 20 magnification. p< 0.05, p< 0.01.
Fig. 3. Sost activation in the injured joint is TNFa and NF-kB dependent. Time line for IA administration of NF-kB inhibitor (BAY-11-7082) and TNFa
inhibitor (neutralizing antibody) (A). Immunohistochemical staining of cartilage (Col2a; green), Sost (red), and nucleus (DAPI; blue) between vehicle
(DMSO or PBS) and BAY-11-7082 (B) or TNFa antibody (C) treated injured joints.
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the cartilage. Osteocyte expression in the femoral cortices was
unaffected by injury (Fig. 2D, H, L). Transcriptionally, we
observed a significant increase in Sost at 3 and 4 days after
injury (Fig. 2M), and by RNA-seq, injured SOSTTG had 1.5-fold
greater Sost/SOST levels (mouseþ human) than injured controls
(mouse only), at 1 day after injury. These findings suggest that
sclerostin expression is inducible in the articular chondrocytes
by traumatic joint injury and confirms the tissue-specific
overexpression of SOST in SOSTTG, which collectively express
higher levels of Sost/SOST proteins in the articular chondrocytes
than inWT injured joints. We examined all areas of the joint and
found cells turning on Sost post-injury only in the articular
chondrocytes (Supplemental Fig. S2). The human transgene also
contains two other transcripts, MEOX1 and DUSP3, therefore we
also quantified human and mouse transcript levels in injured
and uninjured joints, at 1 day after injury for these genes. Both
MEOX1 and DUSP3were expressed at very low levels (<6 FPKM),
8-fold less than human SOST levels (50 FPKM) (Supplemental
Fig. S3).
Previous studies have shown that inflammatory cytokine
TNFa activates Sost in an NF-kB-dependent manner in
osteocyte-like cells, and it was suggested that NF-kB binds to
the Sost promoter.(29) To explore the possibility of direct
transcriptional activation of Sost by inflammation, we searched
the Sost genomic locus for NF-kB confirmed DNA binding sites
using chromatin immunoprecipitation data sets (ChIP-seq). We
identified three NF-kB ChIP-seq hits in the Sost locus that map to
the promoter and two human/mouse evolutionary conserved
regions (ECRs;>100bp/>70% nucleotide identity) downstream
of Sost and within the Van Buchem deletion region(15,16)
(Table 1). Using ATDC5 cell line, we have confirmed that Sost
expression is upregulated by TNFa treatment (Supplemental
Fig. S4B) and that 2/3 Chip-seq candidate regions (Supplemental
Fig. S4A) exhibit enhancer activity in vitro (Supplemental
Fig. S4C). To determine whether Sost activation in the injured
joint is NF-kB dependent, C57Bl/6 injured animals received three
intra-articular (IA) injections of an NF-kB inhibitor (Bay-11-7082)
or TNFa neutralizing antibody, starting 4 hours post-injury
(Fig. 3A). Histological examination of injured joints showed that
both the NF-kB inhibitor and the TNFa antibody prevented the
activation of Sost in the cartilage of the injured joints in contrast
to IA injections with vehicle (DMSO or PBS) (Fig. 3B, C). These
data suggest that inflammatory cytokines such as TNFa in the
injured joint activate Sost expression via its promoter and/or a
distal ECR in chondrocytes in an NF-kB-dependent manner.
Transcriptionally Sost expression was also reduced to pre-injury
levels in injured joints treatedwith NF-kB inhibitor and the TNFa
antibody (Supplemental Fig. S5).
Overexpression of SOST reduced osteophyte formation
in PTOA
Because Sost modulates bone formation,(14,16) we next exam-
ined osteoarthritic remodeling by quantifying the gain in
osteophyte volume and the loss in subchondral trabecular bone
at 6, 12, and 16weeks after injury bymCT (Fig. 4). Consistent with
the established catabolic role of Sost in bone, Sost-/- injured
joints proceeded to synthesize 50% and 28% more ectopic
bone than WT by 12 and 16 weeks after injury, respectively
(Fig. 4A, B). Although no significant differences were observed
between SOSTTG and WT joints at both 6 and 12 weeks post-
injury, 50% and 65% less osteophyte volume was measured
in SOSTTG injured joints at 16 weeks post-injury than in WT or
Sost-/-, respectively (Fig. 4B). Between 12 and 16 weeks post-
injury, both WT and Sost-/- joints built significant amount of
osteophytes, whereas SOSTTG injured joints acquired an
insignificant amount of new osteophyte volume. Whereas
both WT (27.2 3%) and SOSTTG (21.5 10%) injured joints
lost significant subchondral bone volume in the femoral
epiphysis relative to the uninjured contralateral joints, Sost-/-
injured joints were protected from bone loss (Fig. 4C). These
findings suggest that SOST overexpression protects the injured
joint from excessive osteophyte formation, whereas lack of Sost
protects the femur from bone loss resulting from disuse or injury
mediated by elevated catabolic activity in the subchondral
bone.
SOST inhibits the activity of cartilage matrix remodeling
enzymes in injured joints
To determine whether transgenic SOST affects the activity of
matrix metalloproteinases (MMPs), catabolic activity known to
degrade articular cartilage, we visualized and quantified MMP
activity using a fluorescent substrate of MMPs (MMPSense750)
in vivo, 3 days post-injury (Fig. 5A). Although both WT (Fig. 5D)
Fig. 4. SOSTTG joints are protected from excessive osteophyte formation, while Sost-/- joints are protected from subchondral bone loss in injured joints.
mCT representation of mouse injured joints at 6 and 16 weeks post-injury. Darker regions in the injured scans depict ectopic bone nodules (A).
Osteophyte volume (gray area in A) was quantified at 6, 12, and 16 weeks post-injury and compared between genotypes (B). Subchondral trabecular
bone volume to total volume ratio was quantified and analyzed between injured and uninjured joints at 6, 12, and 16 weeks post-injury. Scale
bar¼ 1mm. p< 0.05, p< 0.01, p< 0.001.
1110 CHANG ET AL. Journal of Bone and Mineral Research
and Sost-/- (Fig. 5E) injured joints displayed similar levels of MMP
activity, 2.65-fold activation above the endogenous levels of
the uninjured joint, activation in the SOSTTG injured joint was
significantly lower (2-fold less) (Fig. 5B, F), suggesting that SOST
inhibits the activation of proteolytic enzymes known to degrade
the articular cartilage matrix. Similarly, when WT injured joints
were dosed IA with recombinant mouse Sost protein (rmSost)
immediately after injury (Fig. 5A), a significant decrease in the
levels of activated MMPs (35.8 17%) was observed compared
with PBS controls (Fig. 5B, G, H). Because MMPSense is a broad-
range substrate for a wide range of MMPs, we assessed both
mRNA mmp gene activation in response to injury by RNAseq
(Supplemental Fig. S5S) and evaluated protein expression at
1 day after injury in injured and uninjured contralateral joints of
WT, Sost-/-, and SOSTTG mice for MMPs 2, 3, 7, 9, 12, 13, 14, and
furin. The expression levels of activated MMP2 and MMP3 were
similar in injured and uninjured SOSTTG joints compared withWT
and Sost-/- (Supplemental Fig. S6), which had high levels in the
injured joints, suggesting that elevated levels of SOST
significantly reduced MMP activity and cartilage degradation
after ACL tear. No other MMPs examined had a change either in
mRNA expression or protein (Supplemental Figs. S6 and S7).
Furthermore, MMP reduction was independent of b-catenin
because activated b-catenin levels were the same in both WT
and SOSTTG injured joints (Supplemental Fig. S8).
Discussion
Significant evidence exists that implicates Wnt signaling to have
opposing effects on bone and cartilage; hence, modulation of
Wnt signaling in the musculoskeletal system can contribute to
both osteoporotic (OP) and osteoarthritic (OA) outcomes.(30)
However, the multitude of Wnt signaling participants, including
ligands, receptors, co-receptors and inhibitors, has painted a
picture of a pleiotropic Wnt signaling with many possibly
redundant roles, hindering us from clearly delineating the role of
specific Wnt molecules in the development of degenerative
disorders like OA and OP. Since the discovery by Chan and
colleagues(17) that Sost is upregulated in focal areas of damaged
cartilage in a sheep and mouse model of OA, conflicting reports
by Roudier and colleagues(28) have emerged about the impact
loss of Sost has on the development of OA. Here, we argue that
although Sost loss of function may slightly increase the severity
of PTOA in described mouse models,(6,28) gain of function or
ectopic administration of Sost has a significant beneficial effect
on the progression and outcomes of PTOA.
In particular, elevated levels of SOST/Sost in the joint (either in
transgenic mice or through intra-articular administration)
significantly reduce the expression and hinder the activity of
catabolic enzymes (MMPs 2 and 3) known to degrade the
cartilage extracellular matrix. High levels of Sost in the joint
therefore help the articular cartilage maintain its integrity
subsequent to trauma by opposing the normal upregulation of
cartilage metabolic enzymes activated by inflammation. Be-
cause Wnt ligands have been shown to increase the expression
of MMPs in the human synovium as well as to stimulate the
chondrocyte metabolic action in rabbit models of OA,(31) we
propose a mechanism by which joint injury triggers the
secretion of IL1, IL-6, and TNFa by immune cells; these cytokines
in turn activate the NF-kB pathway to mediate the classic
inflammatory response in many cell types,(32) while simulta-
neously activating Sost expression in articular chondrocytes
(Fig. 6). NF-kB-dependent activation of Sost has been previously
demonstrated, where constitutively active IKK2 (IKK2ca) expres-
sion led to increased expression of Sost in osteoblasts and
chondrocytes.(33) Furthermore, consistent with the findings that
IL1a stimulates Sost expression,(17) we have identified several
NF-kB putative enhancers upstream of Sost that may be
responsible for the transcriptional activation of Sost in cartilage
(Table 1) and that injury-mediated activation is NF-kB depen-
dent. High levels of Sost inhibit MMPs by an unknown
Fig. 5. SOSTTG andWT injured joints treated with recombinant Sost (rmSost) protein have reduced levels of activated MMPs post-injury. MMPSense was
administered IV 5 hours post-injury; rmSost was delivered IA post-injury, andmean fluorescence intensity wasmeasured 3 days post-injury as depicted in
A. SOSTTG- and rmSost-treated injured joints displayed significantly less fluorescence than Sost-/- orWT control joints (B). Representative ex vivo images of
WT uninjured (C) and injured WT (D), Sost-/- (E), and SOSTTG (F). Injured joints show reduced fluorescence in SOSTTG (F). Similarly, rmSost-treated injured
joints (H) show less fluorescence than PBS controls (G). p< 0.01, p< 0.001.
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mechanism; however, this inhibition may be upstream or
independent of b-catenin activation (Supplemental Fig. S8),
consistent with Bouaziz and colleagues(6) findings. Activated
MMPs 2/3 protein levels were reduced in SOSTTG-injured joints
compared with WT and Sost-/--injured joints (Supplemental
Fig. S6), suggesting that elevated levels of SOST in SOSTTG joints
inhibit cartilage degradation after injury, through the selective
inhibition of MMPs 2 and 3 expression (Fig. 5). A parallel
mechanism of MMP activation, by inflammatory triggers, may
also be repressed by a Sost feedback regulatory loop.(34)
Wehmeyer and colleagues recently proposed that sclerostin
blocks TNFa signaling in fibroblast-like synoviocytes;(34) there-
fore, Sost may contribute to a feedback-inhibitory loop in the
joint. Consistent with their findings, we identified elevated
expression levels of Relb and Fos, two transcription factors
activated by TNFa signaling, in Sost-/- joints compared with WT
controls (Supplemental Fig. S9). Furthermore, inflammatory
suppression of Wnt signaling suggests other antagonists may
play a similar regulatory role in OA pathogenesis, including
Dickkopf (DKK)-1, secreted frizzled-related protein I (sFRP-1),
WNT inhibitory factor 1 (WIF1), and Notum, which remains to be
explored.
Although prior work had primarily referred to Sost as an
exclusively osteocyte-derived protein, our work further builds
upon the findings that Sost has inducible activation in
chondrocytes after injury. Here we show that Sost does not
activate exclusively in damaged focal areas(17) of articular
cartilage, but rather turns on in the deep zone immediately after
injury (Fig. 2). This discrepancy may be dependent on the injury
model used. Although the tibial compression OA injury is
noninvasive, this injury method is more severe than the surgical
destabilization of medial meniscus (DMM) but slower in
developing OA. This difference may account for the difference
in Sost expression in chondrocytes. Moreover, our data suggest
a uniform upregulation of Sost in injured cartilage (Fig. 2) with
no obvious fibrillation or clefting of the cartilage. A limitation of
the study is the limited number of time points examined (1 day,
6 weeks, 12 weeks, 16 weeks), intermediate time points (14
weeks) post-ACL injury may have consistent Sost expression and
may reveal other aspects of Sost-MMP relationship.
The opposing effects of Sost on bone and cartilage are further
supported by clinical data that correlate high levels of plasma
sclerostin with increased fracture risk(35) and low levels of Sost in
both OA patient-derived plasma and synovial fluid.(36) The
mechanism by which sclerostin levels are reduced in circulation
and in the synovial fluid of OA patients is unknown; nevertheless,
our intra-articular administration of Sost significantly reduced
MMP activity shortly post-injury, suggesting that Sost may
represent a biomarker of OP and OA but may also have a
therapeutic benefit in injured joints. The mechanism of Sost
upregulation after injury may have two potential beneficial
outcomes. First, NF-kB upregulates Sost, and Sost in turn reduces
MMP activity. The reduction in MMP activity may be direct or
indirect, and one potential route is via a negative feedback loop
where Sost tempers the immune responses. Second, Sost inhibits
osteophyte formation most likely by inhibiting Wnt signaling in
calcifying cartilage (Fig. 6). Inflammatory triggers have been
previously demonstrated to upregulate MMPs,(37,38) suggesting
that a negative feedback loop is the most likely mechanism of
action. Overall, our observation ofMMP reduction post Sost-intra-
articular administrations suggests that Sost may greatly contrib-
ute to PTOA outcome, if administered to the synovium
immediately after injury and after surgical stabilization of the
injured joint. Furthermore, Sost administration to the injured joint
may also prevent osteophyte chondrocyte formation and the
accumulation of ectopic bone that may reduce mobility and
increasepain in the joint, thus abalancebetween theanabolic role
of Sost in cartilage and the catabolic role of Sost in bone may be
beneficiallymanipulated topromote favorableoutcomes inPTOA.
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